Measurement of Circulating Levels of VEGFA, P1GF, and VEGFR1

Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Boulevard, EPS Suite 600, Room 6070, Rockville, MD 20852, UNITED STATES. Description The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), Epidemiology and Biostatistics Program plans to procure on a sole source basis services from Children's Hospital Boston, Clinical & Epidemiologic Research Laboratory, 300 Longwood Avenue, Boston, MA 02115-5724 for the measurement of circulating levels of VEGFA, P1GF, and VEGFR1. This acquisition will be processed in accordance with simplified acquisition procedures in FAR Part 13.106 (b)(1). The North American Industry Classification System code is 541380 the business size standard is $14.0 million. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. Period of Performance: Performance shall be for twelve (12) months from date of award. It has been determined that there is no opportunity to acquire green products or services under this contract. The Division of Cancer Epidemiology and Genetics (DCEG) is an intramural research program of the National Cancer Institute (NCI), National Institutes of Health (NIH) that conducts population and multidisciplinary research to discover the genetic and environmental determinants of cancer and new approaches to cancer prevention. The Epidemiology and Biostatistics Program is evaluating the association of angiogenic profile in the risk of postmenopausal breast cancer risk using samples collected in the screening arm of the Prostate, Lung, Colorectal and Ovarian cancer screening trial. The purpose of this requirement is to measure circulating levels of soluble vascular endothelial growth factor (VEGF1), vascular endothelial growth factor (VEGFA) and placental growth factor (PlGF) in serum using enzyme-linked immunosorbent assays (ELIZA), and to compare these levels between breast cancer cases and matched controls. Children's Hospital Boston, Clinical & Epidemiologic Research Laboratory is the only know contractor that that can fulfill the requirements of this project. In healthy non-pregnant women, levels of circulating VEGFA, VEGFR1, and PlGH are difficult to measure, since levels tend to be below the limit of detection of most assays. Using a newly launched Roche kit, Children's Hospital Boston, Clinical & Epidemiologic Research Laboratory has shown that these angiogenic factors can be detected reliably in non-pregnant women, with inter- and intra-batch CVs of <=5% for pre- and postmenopausal samples. This highly sensitive kit is only available for research purposes in the United States, and Children's Hospital Boston is the only known laboratory that has demonstrated the ability to quantitate these analytes using this state of the art technology (Roche kit) to measure very low concentrations with a total volume of 0.5 ml of serum per subject. This is not a solicitation for competitive quotations. However, if any interested party believes they can meet the above requirement, they may submit a statement of capabilities. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the NCI Office of Acquisition on or before 11:00 AM EST on July 31, 2012. No electronic capability statements will be accepted (i.e. email or fax) an original and one copy must be sent to the NCI Office of Acquisition to the address stated above. All questions must be in writing and can be faxed +1 (555) 000-0000 or emailed to Laura Glockner, Contract Specialist at contact@example.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) www.ccr.gov and the Online Representations and Certifications Applications (ORCA), http://orca.bpn.gov. No collect calls will be accepted. Please reference solicitation number NCI-120103-LG on all correspondence.